Long‐term results with a long‐acting formulation of D‐TRP‐6 LH‐RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study

Ninety‐five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D‐TRP‐6 LH‐RH (“Decapeptyl”) for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn‐RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down‐regulation of testicular LH receptors. Of 88 patients evaluable for response, about one‐half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D‐TRP‐6 LH‐RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

[1]  S. Lightman,et al.  RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMA , 1985, The Lancet.

[2]  L. Boccon‐Gibod,et al.  [Treatment of advanced prostatic cancer with a gonadorelin agonist, dTrp6 LHRH. 41 cases]. , 1985, Presse medicale.

[3]  W F Hendry,et al.  Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. , 1985, British medical journal.

[4]  K. Walker,et al.  An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections. , 1985, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  A. Howell,et al.  Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. , 1985, British medical journal.

[6]  A. Schally,et al.  Treatment of prostatic carcinoma with D‐Trp‐6‐LH‐RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed‐release preparations , 1985 .

[7]  M. Brady,et al.  A reexamination of the stable category for evaluating response in patients with advanced prostate cancer , 1984, Cancer.

[8]  J. Misset,et al.  DISEASE FLARE INDUCED BY LUTEINISING HORMONE RELEASING HORMONE ANALOGUES IN CANCER PATIENTS , 1984, The Lancet.

[9]  R. Santen,et al.  Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. , 1984, The Journal of clinical endocrinology and metabolism.

[10]  J. Lindner,et al.  A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. , 1984, The Journal of clinical investigation.

[11]  A. Howell,et al.  TREATMENT OF ADVANCED PROSTATIC CANCER WITH LHRH ANALOGUE ICI 118630: CLINICAL RESPONSE AND HORMONAL MECHANISMS , 1983, The Lancet.

[12]  A. Schally,et al.  Inhibition of prostate tumors by agonistic and antagonistic analogs of LH‐RH , 1983, The Prostate.

[13]  M. Koutsilieris,et al.  Gonadotropin‐releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma , 1983, The Prostate.

[14]  M. Schmidt-gollwitzer,et al.  SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA A New Therapeutic Approach? , 1982, The Lancet.

[15]  D Ackman,et al.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Corbin.  From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. , 1982, The Yale journal of biology and medicine.

[17]  A. Schally,et al.  Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. , 1981, The Journal of clinical investigation.

[18]  A. Schally,et al.  LH‐RH Agonists and Antagonists , 1980, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  J. Pickren,et al.  Current Status of Classification and Staging of Prostate Cancer , 1980, Cancer.

[20]  A. Schally,et al.  Recent approaches to fertility control based on derivative of LH-RH. , 1980, Vitamins and hormones.

[21]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[22]  H. Meyer-Rienecker,et al.  PATHOGENESIS OF MULTIPLE SCLEROSIS , 1975, The Lancet.

[23]  J. Baak,et al.  Letter: The thymus and sudden unexplained infant death. , 1974, Lancet.

[24]  Day Pr.  Letter: Care of children's eyes. , 1973, Lancet.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .